Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
June 18, 2019
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, David Vlerick, Robert A. Kastelein
Abstract: The present invention relates to a semiconductor composition including an inorganic semiconducting material and an organic binder. The present invention further relates to an electronic device comprising a semiconducting layer consisting of such semiconductor composition.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
June 18, 2019
Assignee:
Merck Patent GmbH
Inventors:
Klaus Bonrad, Matthias Rehahn, Nicole Kolmer-Anderl, Paul Mundt
Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG1, MG2, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and in particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
Type:
Application
Filed:
May 11, 2017
Publication date:
June 13, 2019
Applicant:
MERCK PATENT GMBH
Inventors:
Kevin ADLEM, Patricia SAXTON, Hassan ARASI
Abstract: The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.
Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.
Abstract: The present invention relates to a vessel comprising a device, said device being a sensor or an information storage device or both, and a communication means to transfer data from said vessel to a receiver. The present application also relates to a system, for example a storage system, comprising such vessel.
Type:
Application
Filed:
June 2, 2017
Publication date:
June 13, 2019
Applicant:
Merck Patent GmbH
Inventors:
Brian DANIELS, James KUGLER, Owen LOZMAN, Wiebke DONDRAS, Toby CULL, Mark JAMES, Gerald MUELLER
Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetra-cyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
Type:
Application
Filed:
August 14, 2017
Publication date:
June 13, 2019
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Wensheng Yu, LING Tong, Joseph A. Koziowski, Craig: A Coburn, De-yi J. Yang, Deyou Sha, Jae-Hun. Kim, Michael Dwyer, Kartik M. Keertikar, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang
Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
Type:
Application
Filed:
May 23, 2017
Publication date:
June 13, 2019
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
Abstract: The present invention relates to a liquid crystalline medium which comprises one or more mesogenic compounds selected from the group of compounds of formulae I and II as set forth in claim 1, one or more chiral compounds and one or more polymerisable compounds, to a composite system obtained from or respectively obtainable from the medium by polymerising the one or more polymerisable compounds, and to liquid crystal displays comprising the composite system, in particular displays operating in reflective mode. The present invention further relates to a process for preparing the composite system comprising spatially selective polymerisation.
Abstract: Electronic device and associated methods with multiple well areas located on a common substrate, where each well area is defined by at least three bank structures that form the side walls of the well area. Within each well area, there are at least two electrode segments where the electrode segments are separated laterally by at least one insulating bank where the insulating bank(s) are thicker than the electrode segments. There is at least one charge transporting layer completely filling the well area in direct contact and overlying both the electrode segments and the insulating bank(s). The well areas are filled using solution methods such as inkjet. Such devices have improved uniformity across the active areas.
Type:
Application
Filed:
August 14, 2017
Publication date:
June 13, 2019
Applicants:
Merck Patent GmbH, Merck Patent GmbH
Inventors:
Li Wei TAN, Peter LEVERMORE, Daniel WALKER
Abstract: The present invention is related to a method for the production of single crystalline MgTiO3 flakes, in particular in the geikielite crystal structure, to single crystalline MgTiO3 flakes obtained by this method as well as to the use thereof, in particular as pigments in several application media.
Abstract: The invention relates to novel mixtures of substituted fullerenes, to their use in organic electronic (OE) devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these fullerene mixtures.
Type:
Grant
Filed:
August 3, 2015
Date of Patent:
June 11, 2019
Assignee:
MERCK PATENT GMBH
Inventors:
Graham Morse, Jonathan Henry Wilson, Nicolas Blouin, Solene Bechu
Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.
Abstract: Effect pigments based on Al2O3 flakes with high weather resistance and less photoactivity and to their use thereof in paints, industrial coatings, automotive coatings, printing inks, cosmetic formulations. The effect pigments have a ratio of the amount by weight of Al2O3 of the Al2O3 flake and the amount by weight of the metal oxide(s) of the coating layer(s) in the range of from 27:73 to 83:17 based on the total weight of the effect pigment.
Type:
Application
Filed:
December 19, 2018
Publication date:
June 6, 2019
Applicant:
Merck Patent GmbH
Inventors:
Sabine SCHOEN, Michael JUNGNITZ, Stefan SCHLUETER, Kirsten FRITSCHE, Carsten PLUEG, Stephanie ANDES, Ulrich SCHOENEFELD
Abstract: Disclosed are taste-masked pharmaceutical formulations of raltegravir comprising coated API granules mixed with a screened powder excipient blend in either tablet or sachet form. The core and coated granules are produced using a Wurster process for enhanced control of particle size. Also disclosed are methods of treating HIV, e.g., in pediatric populations.
Type:
Application
Filed:
December 14, 2018
Publication date:
June 6, 2019
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Karen Cassidy Thompson, Kimberly Nicole Kaighn, Indra Neil Mukherjee, Catherine Elizabeth Diimmler, Hedy Teppler Weiser, Christopher Mancinelli
Abstract: Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
Abstract: The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Type:
Grant
Filed:
September 27, 2015
Date of Patent:
June 4, 2019
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Nigel Liverton, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
Abstract: This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by the processes of the invention are useful for treating Alzheimer's disease and other diseases (e.g., cognitive impairment, schizophrenia, pain disorders, and sleep disorders) mediated by the muscarinic M1 receptor.
Abstract: This disclosure provides methods of making certain 7-aminocephem derivatives useful in the manufacture of cephalosporin antibiotic compounds.
Type:
Grant
Filed:
March 14, 2018
Date of Patent:
June 4, 2019
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Kristos Adrian Moshos, Valdas Jurkauskas